UNICA IRIS Institutional Research Information System

CHESSA, LUCHINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 156.909
NA - Nord America 7.431
AS - Asia 1.074
AF - Africa 29
SA - Sud America 24
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 6
Totale 165.495
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 154.508
US - Stati Uniti d'America 7.381
SE - Svezia 725
UA - Ucraina 724
CN - Cina 713
DE - Germania 248
GB - Regno Unito 223
FI - Finlandia 220
FR - Francia 96
SG - Singapore 96
VN - Vietnam 79
CA - Canada 44
IN - India 44
NL - Olanda 26
HK - Hong Kong 21
RU - Federazione Russa 21
AU - Australia 20
IE - Irlanda 18
BE - Belgio 15
IR - Iran 14
TR - Turchia 14
TW - Taiwan 14
KR - Corea 12
AT - Austria 11
ES - Italia 11
IL - Israele 10
JP - Giappone 10
BR - Brasile 9
CH - Svizzera 8
CO - Colombia 8
CZ - Repubblica Ceca 8
IQ - Iraq 8
ZA - Sudafrica 8
MY - Malesia 7
RO - Romania 7
BD - Bangladesh 6
DK - Danimarca 6
ID - Indonesia 6
EG - Egitto 5
BG - Bulgaria 4
MX - Messico 4
PK - Pakistan 4
RS - Serbia 4
UG - Uganda 4
AE - Emirati Arabi Uniti 3
AP - ???statistics.table.value.countryCode.AP??? 3
AR - Argentina 3
EU - Europa 3
MK - Macedonia 3
NG - Nigeria 3
NO - Norvegia 3
PE - Perù 3
PT - Portogallo 3
SI - Slovenia 3
TH - Thailandia 3
HU - Ungheria 2
KE - Kenya 2
LT - Lituania 2
LU - Lussemburgo 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
PH - Filippine 2
AL - Albania 1
BF - Burkina Faso 1
BJ - Benin 1
CG - Congo 1
CY - Cipro 1
DZ - Algeria 1
EC - Ecuador 1
GE - Georgia 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
JO - Giordania 1
KZ - Kazakistan 1
LB - Libano 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
MU - Mauritius 1
PA - Panama 1
PL - Polonia 1
SD - Sudan 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
UZ - Uzbekistan 1
Totale 165.495
Salva come PNG Salva come JPEG
Città #
Cagliari 153.188
Fairfield 915
Woodbridge 783
Chandler 734
Houston 596
Nyköping 520
Ashburn 455
Ann Arbor 408
Jacksonville 392
Wilmington 348
Seattle 344
Cambridge 294
Boardman 202
Dearborn 192
Boston 180
Nanjing 146
Beijing 122
Helsinki 119
New York 109
Rome 100
Shanghai 91
San Diego 79
Dong Ket 78
Milan 71
Redwood City 70
Nanchang 50
Hebei 37
Shenyang 37
Norwalk 35
Guangzhou 32
Jiaxing 32
Changsha 31
London 30
Washington 27
Tianjin 25
Paris 24
Mountain View 22
Orange 22
San Mateo 22
Sassari 22
Toronto 21
Verona 20
Nottingham 19
Hong Kong 16
Atlanta 15
Kunming 14
Brussels 13
Jinan 13
Los Angeles 13
Auburn Hills 12
Dublin 12
Pune 12
Redmond 12
Bergamo 11
Borås 11
Taizhou 11
Genova 10
Hefei 10
Ningbo 10
Taipei 10
Naples 9
Saint Petersburg 9
Vienna 9
Wuhan 9
Bari 8
Brescia 8
Dallas 8
Ferrara 8
Gyeongsan-si 8
Huntingdon 8
Leawood 8
Olbia 8
Palermo 8
Phoenix 8
Zhengzhou 8
Augusta 7
Bogazici 7
Florence 7
Napoli 7
Nuoro 7
Padova 7
Renton 7
Santadi 7
Bogotá 6
Chicago 6
Falls Church 6
Porto Torres 6
Turin 6
Täby 6
Bengaluru 5
Chiswick 5
Columbus 5
Iowa City 5
Khulna 5
La Spezia 5
Ladispoli 5
Melbourne 5
Ploaghe 5
Sìnnai 5
Tortolì 5
Totale 161.520
Salva come PNG Salva come JPEG
Nome #
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.056
Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis: a possible pathogenetic role ? 3.003
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma 2.901
Gastrointestinal Coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management 2.842
Altered profile of salivary proteins in patients with Autoimmune Hepatitis 2.670
Role of interferon lambda 4 and ALT levels in optimising treatment of HCV for patients with low-stage fibrosis 2.637
HLA-G is highly expressed by plasma cells infiltrating hepatic tissue of patients affected by autoimmune hepatitis 2.558
Hippocampal axis dysfunction evaluation by Rey-Osterrieth Complex figure test (RCFT) should be included in minimal hepatic encephalopathy (MHE) assessment 2.492
Impact of natural killer (NK) cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients 2.461
Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis 2.421
Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible? 2.386
FATTORI IMPLICATI NELLA STORIA NATURALE DELL'INFEZIONE DA VIRUS DELTA:IL RUOLO DEGLI INTERFERONI 2.295
Impact of direct-acting antiviral drugs for chronic hepatitis C on mood: Preliminary results from a longitudinal study 2.266
Association of chronic hepatitis C with recurrent brief depression 2.252
Behavior of bone mass in long-term HAART patients 2.208
IMPACT OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS ON PROGRESSION OF HEPATOCELLULAR CARCINOMA 2.165
Role of natural killercells receptors on the development and progression of hepatocellularcarcinoma 2.142
INFLUENZA DEI POLIMORFISMI DELL’INTERFERONE LAMBDA NELLA STORIA NATURALE DELLA INFEZIONE CRONICA DA HBV: COINCIDENZA O REALTÀ? 2.139
Safety and efficacy of direct-acting antivirals in transfusion-dependent thalassemic patients with chronic hepatitis C 1.938
Dynamics of TT virus infection in a cohort of HCV-infected patients achieving sustained virologic responce after treatment with direct-acting antivirals 1.910
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in patients with chronic HCV infection treated with direct antiviral agents 1.878
A multivariate approach for the brain impairment in patients with liver cirrhosi 1.847
Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis 1.810
Role of HLA-G in autmoimmune hepatitis 1.785
null 1.742
Efficacy and tolerability of treatment with the new direct acting antivirals (DAAs) in thalassemic patients with chronic Hepatitis 1.718
null 1.710
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D 1.686
null 1.666
null 1.610
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in co-infected HIV-HCV patients treated with the new direct acting antivirals (DAAs) 1.592
Long-latency potential study in minimal hepatic hencephalopaty 1.569
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 1.555
SAFETY AND EFFICACY OF PEG-IFN alpha 2a AND RIBAVIRIN FOR TREATMENT OF HEPATITIS C IN SARDINIAN ADULT PATIENTS WITH THALASSEMIA MAJOR: A SINGLE CENTRE REAL LIFE EXPERIENCE 1.518
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 1.511
Is the Inversion in the Trend of the Lethality of the COVID-19 in the Two Hemispheres due to the Difference in Seasons and Weather? 1.435
null 1.424
EVALUATION OF MILD COGNITIVE DYSFUNCTION BY MONTREAL COGNITIVE ASSESSMENT TEST IN PATIENTS WITH CHRONIC HCV INFECTION 1.417
Multidimensional geriatric assessment in elderly HIV patients 1.378
HepaDisk – A new quality of life questionnaire for HCV patients 1.377
The climate in the European Union and the enlarged European Region is a determinant of the COVID-19 case fatality ratio 1.377
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 1.361
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 1.352
null 1.208
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 1.203
Individualized long-term treatment of chronic hepatitis C with interferon alpha (IFN alpha)-2a. 1.179
Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database 1.174
Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy 1.153
Can antiretroviral therapy modify the clinical course of HDV infection in HIV positive patients? 1.135
Optimization of hepatitis C virus screening strategies by birth cohort in Italy 1.121
Orthotopic liver transplantation in neurological Wilson desease: case report 1.094
Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort. 1.073
Evolution of the HCV quasispecies and pattern of response to interferon therapy in patients with chronic hepatitis C 1.066
Predictive Factors for Liver Disease Progression Following the Direct Acting Antivirals Induced Sustained Virological Response: Data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) Cohort 1.066
Forecasting liver disease burden 1.047
The COVID-19 incidence in Italian regions correlates with low temperature, mobility and PM10 pollution but lethality only with low temperature 1.023
La quasispecie del virus dell’epatite C: implicazioni biologiche e cliniche 1.016
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 981
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? 979
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 959
Evolution of the viral quasispecies tracked by sequence analysis during interferon treatment of chronic hepatitis C. 951
Risultati preliminari di uno studio di fase II con Sorafenib in pazienti anziani affetti da epatocarcinoma 949
Clinical characterization and economic impact evaluation of antiHCV DAA treatment failure:real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) 920
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An Innovate study protocol 905
Epidemiological and Economic Evaluations According to Daa Treatment Access in Italy Based on Real Life Piter Cohort Data 904
Forecasting Hepatitis C liver disease burden based on real life data. Does the hidden iceberg matter to reach the World Health Organization elimination goals? 882
Long term effectiveness of DAA therapy in patients with chronic HCV and Mixed Cryoglobulinemic Syndrome 861
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 861
Mixed cryoglobulinemia: an important but frequently unrecognized and underestimated HCV-related condition in the real life practice 852
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 845
Optimization of Hepatitis C Virus screening strategies by birth cohort in Italy 841
Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy 823
STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATEDWITH SORAFENIB. INNOVATE STUDY 822
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 808
Distribution of IL28B polymorphism in a cohort of Italians and immigrants with HCV infection: association with viraemia, stage of fibrosis and response to treatment 800
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study 793
Iron concentration and distribution in the newborn liver 790
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV Gruppo 787
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? 781
The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis 780
L'approccio basato sui casi per la diagnosi di malattie epatiche 759
Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection 733
Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort 729
Outcomes of advanced liver disease in patients with chronic hepatitis C with and without HIV coinfection following sustained virological response: a real life evaluation in the PITER cohort 724
Gender differences in HCV chronic liver disease: a reallife evaluation in PITER (PIATTAFORMA ITALIANA PER LO STUDIO DELLA TERAPIA DELLE EPATITI VIRALI) Cohort study. 722
Modeling cost-effectiveness and health gains of a “universal“ versus “prioritized“ hepatitis C virus treatment policy in a real-life cohort 722
Health gains and costs of HCV treatment: a cost effectiveness analysis of two different health policies scenarios simulated in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) real life cohort 721
EFFICACIA A TOLLERABILITÀ DELLA DUAL THERAPY RALTEGRAVIR+DARUNAVIR/RITONAVIR NELLA PRATICA CLINICA 720
Treatment prioritization according to the EASL HCV CPG 2015: a real-life evaluation on the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort 717
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study 704
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 652
HCV-related mixed cryoglobulinemia: data from PITER, a nationwide Italian HCV Cohort study multicentric prospective 644
Real life clinical outcomes in DAA-treatedand untreated patients with HCV advanced liver disease. Interim one year data from the ongoing PITER cohort 639
Fattori predittivi della progressione della malattia del fegato in pazienti con risposta sierologica sostenuta indotta dai DAA: dati della coorte reale PITER. 637
Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy 616
Male gender, genotype 3, previous alcohol use, increased BMI, and diabetes are factors independently correlated to advanced HCV chronic liver disease in Italy: data from PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort study 613
Urinary neopterine as an activity marker in immunological diseases 601
Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination 551
Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful? 542
Treatment of chronic hepatitis D 520
Totale 134.758
Salva come PNG Salva come JPEG
Categoria #
all - tutte 212.711
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 212.711
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.086 0 0 0 0 0 0 0 0 0 0 522 564
2019/202032.114 1.669 903 149 485 12.682 8.108 4.333 886 660 579 545 1.115
2020/202147.853 1.242 1.726 1.799 12.140 9.497 5.470 3.889 3.130 1.499 2.960 2.694 1.807
2021/202213.215 1.217 1.135 703 1.000 958 985 865 724 1.097 996 1.535 2.000
2022/202319.438 2.076 2.643 2.596 1.408 1.692 1.926 893 1.655 1.133 1.086 1.435 895
2023/202418.652 1.023 1.137 1.230 1.719 2.020 3.675 3.466 1.533 1.028 1.470 351 0
Totale 166.025